Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics

Core Viewpoint - Analysts project that Teva Pharmaceutical Industries Ltd. will report quarterly earnings of $0.63 per share, reflecting a 3.3% year-over-year increase, with revenues expected to reach $4.29 billion, a 3% increase from the same quarter last year [1]. Earnings Estimates - There has been a downward revision of 0.7% in the consensus EPS estimate over the last 30 days, indicating a collective reconsideration by analysts of their initial forecasts [2]. - Revisions to earnings projections are crucial for predicting investor behavior, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- COPAXONE- Total' at $101.85 million, a decrease of 31.2% from the prior-year quarter [5]. - 'Revenue- API sales to third parties' is expected to be $156.49 million, reflecting a 3.6% increase year-over-year [5]. - 'Revenue- Other- Total' is projected to reach $259.03 million, indicating a significant increase of 144.4% from the prior-year quarter [5]. Geographic Revenue Insights - 'Geographic Revenue- Europe' is estimated at $1.25 billion, showing a 3.3% increase from the year-ago quarter [6]. - 'Geographic Revenue- International Markets' is projected to be $602.40 million, reflecting a 1.6% increase year-over-year [6]. - 'Geographic Revenue- United States' is expected to reach $2.19 billion, indicating a 3.6% increase from the previous year [7]. Specific Product Revenue - 'Geographic Revenue- United States- Anda' is projected at $358.28 million, a decrease of 4% from the prior-year quarter [7]. - 'Geographic Revenue- Europe- COPAXONE' is expected to be $40.50 million, reflecting a decline of 23.6% year-over-year [7]. - 'Geographic Revenue- International Markets- Generic products' is estimated at $478.57 million, indicating a year-over-year change of -1.5% [8]. Additional Revenue Estimates - 'Geographic Revenue- International Markets- COPAXONE' is projected at $10.83 million, a decrease of 22.7% from the prior-year quarter [9]. - The consensus estimate for 'Geographic Revenue- United States- AJOVY' stands at $50.80 million, reflecting a 21% increase from the year-ago quarter [9]. Stock Performance - Teva's shares have shown a return of -1.3% over the past month, contrasting with the Zacks S&P 500 composite's increase of 4.9% [9].